| Therapeutic | Necitumumab |
| Target | EGFR/ERBB1/HER1 |
| Heavy Chain | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS |
| Light Chain | EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK |
| 100% seqID Fv Structure | 3b2u [Fvs: CD, FG, HL, JK, NO, QR, TU, WX], 3b2v [Fvs: HL], 6b3s [Fvs: CD, FG, HL, JK] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6b3s [Fvs: CD, FG, HL, JK] |
| 100% seqID Structure | 3b2u [Fvs: CD, FG, HL, JK, NO, QR, TU, WX] |
| 100% seqID Structure | 3b2v [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | |
| INN Year Proposed | 2008 |
| INN Year Recommended | 2009 |
| Companies Involved | ImClone Systems, Eli Lilly |
| Conditions Approved | Non-small cell lung cancer |
| Conditions Active | Solid tumours |
| Conditions Discontinued | Colorectal cancer |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
